| Literature DB >> 31578825 |
Yi-Bin Jiang1, Kai-Yan Wei1, Xu-Yang Zhang1, Hua Feng1, Rong Hu1.
Abstract
The predilection site of intracerebral hemorrhage (ICH) is in the basal ganglia, which is rich in white matter (WM) fiber bundles, such as cerebrospinal tract in the internal capsule. ICH induced damage to this area can easily lead to severe neurological dysfunction and affects the prognosis and quality of life of patients. At present, the pathophysiological mechanisms of white matter injury (WMI) after ICH have attracted researchers' attention, but studies on the repair and recovery mechanisms and therapy strategies remain rare. In this review, we mainly summarized the WM recovery and treatment strategies after ICH by updating the WMI-related content by reviewing the latest researches and proposing the bottleneck of the current research.Entities:
Keywords: hemorrhage; regeneration; repair; white matter injury
Mesh:
Substances:
Year: 2019 PMID: 31578825 PMCID: PMC6823871 DOI: 10.1111/cns.13226
Source DB: PubMed Journal: CNS Neurosci Ther ISSN: 1755-5930 Impact factor: 5.243
Figure 1White matter repair mechanism and strategy following ICH. The repair mechanism and strategy of WMI is summarized according to the available literature. The potential therapeutic and current strategies include the following aspects: self‐repair, neuroprotection (reducing neuroinflammation, inhibition of oxidative stress, and reducing excitatory toxicity), regenerative repair (neurogenesis, oligodendrogenesis, angiogenesis, astrogenesis, and axon regeneration), stem cell transplantation, molecular therapy (potential microRNA therapy, gene therapy, and nanotechnology), and clinical treatment (early hematoma clearance, imaging, monitoring treatment, prevention of complications, neuroprotective agents, and early rehabilitation). ICH: intracerebral hemorrhage, WMI: white matter injury
Figure 2The pathophysiological mechanisms of ICH‐induced WMI were summarized. After ICH, WMI can be caused by primary injury and secondary injury. Primary injury is mainly due to the mass effect, and the changes in hemodynamics caused by the formation of hematoma at the bleeding site after ICH. Secondary injury is mainly induced by neuroinflammation caused by cytokines and chemokines, oxidative stress caused by hemoglobin and its metabolites, as well as neuroexcitatory poisoning mediated by glutamate, which further triggers WMI. Although many of these molecular mechanisms are still being explored, the results are WM axonal damage, demyelination, and blood‐brain barrier destruction. ICH: intracerebral hemorrhage, WMI: white matter injury, OL: oligodendrocyte
Repair mechanisms and strategy of white matter injury after intracerebral hemorrhage
| Repair mechanisms | Repair strategy | Specific treatment |
|---|---|---|
| Self‐repair | endogenous clearance of hemoglobin | Upregulation of CD36 |
| endogenous nerve regeneration | Thrombin improves the function of nerve and vascular regeneration | |
| Neuroprotection | Reducing neuroinflammation | Supplementing P2X7R inhibitor |
| Supplementing taurine | ||
| Supplementing curcumin | ||
| Supplementing dimethylamine tetracycline | ||
| Inhibition of oxidative stress | Supplementing ZnPP | |
| Supplementing baicalein | ||
| Regenerative repair | Neurogenesis | transplantation of BMMSCs |
| an exogenous lactic acid injection | ||
| Oligodendrogenesis | Supplementing IGF‐1, PDGF, and FGF‐2 | |
| Inhibin A and Matrilin 2 | ||
| Angiogenesis | EGb761 attenuates neuronal apoptosis induced by ferrous iron | |
| Human umbilical cord tissue‐derived cells | ||
| Repeated exposure to low‐intensity ultrasound | ||
| Selective cathepsin B/L inhibitor | ||
| Astrogenesis | — | |
| Axon regeneration | hydrogels | |
| ADMSC therapy | ||
| Modulation of GPCR signaling | ||
| Stem cell transplantation | Transplantation of BMMSCs, HUCTDCs, and MSCs, and iPSs | |
| Molecular therapy | Potential microRNA therapy | utilizing a unilateral stereotaxic injection to deliver lentiviruses encoding miR‐132, miRNA‐126 or miR‐27b |
| Gene therapy | Knocking down IRAK4, CD47 | |
| Nanotechnology | Using peptide‐based nanofiber scaffold | |
| Clinical treatment | Etiological screening | Imaging |
| Early hematoma clearance | ||
| Monitoring treatment | Vital signs | |
| Blood glucose | ||
| Electrolytes | ||
| Intracranial pressure | ||
| Laboratory parameters | ||
| CT review | ||
| Preventive treatment | Rebleeding | |
| Edema occupying position | ||
| Seizures | ||
| Pneumonia | ||
| Intracranial infections | ||
| Neuroprotective agents | ||
| Hypothermia | ||
| Early rehabilitation |